These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32535767)

  • 1. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
    Kang C; Scott LJ
    Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
    Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
    Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
    Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
    Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
    [No Abstract]   [Full Text] [Related]  

  • 6. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
    Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
    Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect.
    Leroy BP; Fischer MD; Flannery JG; MacLaren RE; Dalkara D; Scholl HPN; Chung DC; Spera C; Viriato D; Banhazi J
    Ophthalmic Res; 2023; 66(1):179-196. PubMed ID: 36103843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
    Weng CY
    Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
    [No Abstract]   [Full Text] [Related]  

  • 10. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
    Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
    Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
    Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
    Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
    Lopez J; Borchert M; Lee TC; Nagiel A
    Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.
    Levi SR; Oh JK; de Carvalho JRL; Mahajan VB; Tsang SH; Sparrow JR
    JAMA Ophthalmol; 2020 Aug; 138(8):919-921. PubMed ID: 32556084
    [No Abstract]   [Full Text] [Related]  

  • 14. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
    Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
    Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first gene therapy for
    Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
    Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice.
    Testa F; Bacci G; Falsini B; Iarossi G; Melillo P; Mucciolo DP; Murro V; Salvetti AP; Sodi A; Staurenghi G; Simonelli F
    Eye (Lond); 2024 Sep; 38(13):2504-2515. PubMed ID: 38627549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
    Bennett J; Maguire AM
    Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
    Kessel L; Christensen UC; Klemp K
    Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
    Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.